Vivimed Labs share price & results
- Mar 2026
- Mar 2026
Hyderabad-based pharma formulator manufacturing and exporting generic and branded-generic tablets, sachets, oral liquids and ophthalmic products, plus contract-manufacturing (CDMO) services for other pharma companies.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 8.0 | −65.2% YoY | Quarterly, as filed | Quarter to Mar 2026 | Revenue from operations as filed. |
| Operating margin | -1815.0 | −1804.0 pts YoY | Operating profit / revenue | Quarter to Mar 2026 | For the quarter; a change is in percentage points. |
| Net profit | -142 | Quarterly, as filed | Quarter to Mar 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. | |
| Return on equity | 83.81 | −7.6 pts | Trailing twelve months | TTM to Mar 2026 | Adjusted profit attributable to owners ÷ average owners’ equity. |
| Free cash flow margin | 10.07 | +15.7 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | -40.17 | −17.5 pts | Trailing twelve months | TTM to Mar 2026 | Revenue change against the same period one year earlier. |
Price
Performance +18.4% 1Y
1Y: ₹4.95 on 31 Jul 2023 → ₹5.86. High ₹26.6 (18 Dec 2025), low ₹4.88 (10 Aug 2026).
- Previous close
- ₹5.97
- Market cap
- ₹49 Cr
- 52-week range
- ₹4.88 – ₹26.6
- Return on equity (TTM to Mar 2026)
- 83.81%
Overview
- Symbol
- NSE:VIVIMEDLAB
- Sector
- Healthcare
- Exchange
- NSE
- Currency
- INR
What Vivimed Labs Limited does
Based on the company's own presentations, annual report and earnings calls.
Vivimed Labs develops and manufactures generic and branded-generic pharmaceutical formulations — tablets, sachets, oral liquids and ophthalmic products — sold through export/regulated-market and domestic branded channels, and also provides contract manufacturing services to other pharmaceutical companies. It began in 1988 as a formulation contract manufacturer and later added API/bulk-drug manufacturing at Bidar, Karnataka (1991), before building out an API-CDMO subsidiary (UQUIFA) and a specialty-chemicals business through acquisitions. The company has since divested/monetised the specialty-chemicals business (personal care to Clariant in 2016; hair-dye and photochromic dyes in 2019) and its stake in UQUIFA (2020–2024), refocusing on the formulations (FDF) business.
Segments
- Export / Regulated-Markets Formulations
- Domestic Branded Business
- Contract Manufacturing (CDMO)
- Manufacturing facilities
- 5 advanced, certified facilities
- R&D centre
- 1 dedicated R&D centre supporting formulation development
- Quality/regulatory certifications
- Health Canada, PIC/S GMP approved
- Export markets/geographies (FY25)
- Canada, EU, CIS, GCC and ROW countries incl. Bolivia, Chile, Vietnam, Tanzania, Philippines, Saudi Arabia, Azerbaijan, Kyrgyzstan, Ukraine, Uzbekistan, Zambia, Mexico
- New R&D / product-development projects signed (FY25)
- 16
- Original manufacturing site
- Bidar, Karnataka — API/bulk-drug plant commissioned 1991
Fundamentals
Ratios, each with its period
Current values with the period they cover; the trend reads across the 6 fiscal years held (Mar 2021 to Mar 2026).
Financials
What the filings say
Net profit, year on year: −3450% (quarter to mar 2026 against mar 2025).
| Line item | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 25 | 22 | 34 | 23 | 18 | 19 | 12 | 8 |
| Expenses | 36 | 23 | 34 | 25 | 18 | 20 | 23 | 145 |
| Operating profit | -11 | -1 | 0 | -2 | -1 | -1 | -11 | -137 |
| Operating margin | −45.0% | −3.6% | −0.5% | −11.0% | −3.0% | −7.0% | −96.0% | −1815.0% |
| Other income | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 1 | 1 | 2 | 1 | 1 |
| Depreciation | 4 | 4 | 6 | 5 | 5 | 5 | 4 | 4 |
| Profit before tax | -15 | -5 | -7 | -4 | -6 | -7 | -17 | -142 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net profit | -15 | -5 | -7 | -4 | -6 | -7 | -17 | -142 |
| EPS (₹ per share) | -1.82 | -0.60 | -0.84 | -0.53 | -0.66 | -0.90 | -2 | -17.14 |
| Line item | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 136 | 104 | 57 |
| Expenses | 170 | 118 | 206 |
| Operating profit | -33 | -14 | -150 |
| Other income | 9 | 4 | 0 |
| Interest | 2 | 1 | 5 |
| Depreciation | 17 | 19 | 18 |
| Profit before tax | -45 | -31 | -172 |
| Net profit | -45 | -31 | -172 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 17 | 17 | 17 | 17 | 17 | 17 |
| Reserves | 441 | 117 | 73 | 42 | -65 | -129 |
| Borrowings | 357 | 377 | 375 | 375 | 384 | 388 |
| Other liabilities | 258 | 286 | 217 | 206 | 588 | 226 |
| Total liabilities | 1,072 | 796 | 681 | 639 | 924 | 502 |
| Fixed assets | 429 | 343 | 326 | 315 | 393 | 286 |
| Capital work in progress | 40 | 21 | 21 | 17 | 21 | 17 |
| Investments | 161 | 161 | 59 | 59 | 168 | 56 |
| Other assets | 442 | 271 | 276 | 248 | 342 | 142 |
| Total assets | 1,072 | 796 | 681 | 639 | 924 | 502 |
| Line item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Cash from operations | 75 | 180 | 25 | 33 | -97 | 6 |
| Cash from investing | 3 | -138 | -11 | -2 | 100 | -4 |
| Cash from financing | -91 | -46 | -13 | -35 | -6 | -3 |
| Net cash flow | -13 | -5 | 1 | -3 | -2 | -1 |
| Free cash flow | 78 | 115 | 14 | 31 | -99 | 2 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 133 | 106 | 104 | 159 | 161 | 284 |
| Inventory days | 954 | 608 | 106 | 340 | 354 | 56 |
| Days payable | 124 | 95 | 77 | 211 | 211 | 266 |
| Cash conversion cycle | 963 | 619 | 134 | 289 | 304 | 73 |
| Working capital days | 213 | 116 | -299 | -311 | -513 | -1828 |
| Return on capital employed | 2.0% | −3.0% | −44.0% | −9.0% | −6.0% | −47.0% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Where revenue comes from
The businesses behind the company’s reported revenue.
Pharma Business contributes 96.0% of reported segment revenue.
Year ended 31 Mar 2024 · Consolidated
- Pharma Business 96.0%
₹143.17 crore
- Speciality Chemicals Business 4.0%
₹5.90 crore
| Business segment | Revenue · ₹ crore | Share |
|---|---|---|
| Pharma Business | 143.17 | 96.0% |
| Speciality Chemicals Business | 5.90 | 4.0% |
Share = segment revenue ÷ total segment revenue, before intersegment adjustments.
How these numbers add up
- Total segment revenue
- ₹149.07 crore
- Intersegment adjustment
- Not reported
- Net segment revenue
- ₹149.07 crore
Intersegment transactions are between the company’s own businesses. Net segment revenue can differ from income-statement revenue because reporting definitions differ.
Source: FinEdge · Last checked 19 Sept 2026. Reported segment names are kept as supplied.
How the mix has moved
Speciality Chemicals Business grew from 4% to 8% of revenue over the last year.
| Segment | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | YoY growth latest quarter |
|---|---|---|---|---|---|
| Pharma Business | 96% | 97% | 100% | 92% | — |
| Speciality Chemicals Business | 4% | 3% | — | 8% | — |
Share of reported segment revenue by quarter, consolidated basis, as filed. A quarter the company did not report is left blank, never carried forward.
See how segments are shifting across companies → Segment Shift
Ownership
Who owns it
Public hold 90.66% as of Mar 2026.
- Promoters 7.57%
- Foreign institutions 1.64%
- Domestic institutions 0.00%
- Government 0.12%
- Public 90.66%
Who bought this quarter
since Dec 2025
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- FPI fund newly disclosed 1.47% held
- newly disclosed 1.12% held
The same filing shows 1 holder trimming and 3 off the list — both are in the register beside this.
Who is on the register
Named in the Mar 2026 filing
Every holder of Vivimed Labs Limited above SEBI's 1% disclosure line, and what changed since Dec 2025.
| Holder | Stake | Change |
|---|---|---|
| 9.37% | unchanged | |
| 2.81% | unchanged | |
| 1.65% | unchanged | |
| 1.64% | unchanged | |
| 1.63% | unchanged | |
| FPI fund | 1.47% | newly disclosed |
| 1.42% | unchanged | |
| 1.24% | unchanged | |
| 1.12% | newly disclosed | |
| 0.83% | unchanged | |
| 0.52% | unchanged | |
| 0.52% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Start an Inve Case for Vivimed Labs Limited
Free account: one company. Everything above stays public.
Write why you follow Vivimed Labs Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other Healthcare companies
Learn to analyse Vivimed Labs Limited
Guides on how to read this kind of business and the numbers that matter.